A recent study published in the journal Addiction has revealed that injections of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as Ozempic, and glucose-dependent insulinotropic polypeptide (GIP) drugs like Mounjaro, can significantly reduce alcohol intoxication and may also offer benefits for those struggling with opioid addiction.
Researchers analyzed a substantial dataset of 817,309 individuals with a history of alcohol use disorder. Among these, 5,621 participants were prescribed GLP-1 RAs or GIP. The findings indicated that individuals receiving these prescriptions experienced a 50% lower rate of alcohol intoxication compared to those who did not use these medications.
The study suggests that the efficacy of these drugs may extend beyond appetite control; they also appear to influence brain regions associated with addictive behaviors, according to health experts. This dual action could be key in helping individuals manage their addictions.
In a parallel analysis, researchers examined 503,747 individuals with a history of opioid use disorder, out of which 8,103 had been prescribed GLP-1 RAs or GIP. The results showed that those with opioid use disorder who were on these medications had a 40% lower rate of opioid overdose compared to those who were not prescribed these drugs.
The study’s authors concluded that further investigation into the potential of these medications as a novel pharmacotherapy treatment for both alcohol and opioid addiction is warranted. “These results underscore the need for more research on GLP-1 RAs and GIPs as therapeutic options for substance use disorders,” they stated.
The findings come amidst ongoing discussions in the UK about the appropriate use of weight-loss injections. Health Secretary Wes Streeting cautioned against using drugs like Ozempic and Wegovy for aesthetic purposes, such as achieving the “Instagram perfect body.” Meanwhile, opposition leader Sir Keir Starmer emphasized the potential of these treatments to aid individuals in returning to work, thereby contributing to the economy.
Additionally, Prime Minister Rishi Sunak has noted that the introduction of these injections may alleviate some of the pressures on the National Health Service (NHS).
The implications of this research are significant, particularly as healthcare professionals seek innovative methods to combat the rising rates of addiction. As the medical community continues to explore the benefits of GLP-1 RAs and GIPs, there is hope that these medications may offer new pathways for recovery for individuals grappling with alcohol and opioid use disorders.
